Effects of prostaglandin E1 and buflomedil on left ventricular function in patients with severe chronic occlusive arterial disease: A prospective, randomized, double-blind trial

American Journal of Therapeutics

Volumn 4, Issue 11-12, 1997, Pages 375-380

  Kolsch B ^a   Mohr Kahaly, S ^a   Wittlich, N ^a   Reeh, U ^a   Meyer, J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Parameters of left ventricular systolic function; Peripheral occlusive arterial disease; Prostaglandin E1

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFLOMEDIL; PROSTAGLANDIN E1; PROSTAVASIN; PYRROLIDINE DERIVATIVE;

ADULT; AGED; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMIC PARAMETERS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; TREATMENT OUTCOME; ARTICLE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ALPROSTADIL; ARTERIAL OCCLUSIVE DISEASES; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; PYRROLIDINES; VENTRICULAR FUNCTION, LEFT;

EID: 0030608609     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199711000-00006     Document Type: Conference Paper

References (33)

1. 1-Therapie bei AVK im Stadium III/ IV. Therapiewoche 1989;39:2736-2742.
2. 1-Infusionen. Med Welt 1989;40:1501-1503.
3. 1 - Wirkungen und Therapeutische Wirksamkeit. (Eds. Heidrich H, Boehme H, Rogatti W), Springer, Berlin, 1988, pp 95-102.
4. Heidrich H, Ranft J, Peters A: Frueh- und Spaetergebnisse nach intravenoeser Prostavasin-Therapie bei peripher-arteriellen Durchblutungsstoerungen mit Ruheschmerz und Nekrosen. Vasa Suppl 1987;20:202-203.
5. 1 in patients with peripheral vascular disease. Adv Prostaglandin Thromboxane Res 1976;1:429-432.
6. 1 - Wirkungen und Therapeutische Wirksamkeit. (Eds. Heidrich H, Boehme H, Rogatti W), Springer, Berlin, 1988; pp 103-111.
7. 1. Vasa Suppl 1989;28:19-25.
8. 1 bei Diabetikern mit AVK im Stadium IV. Vasa Suppl 1992;35:164-166.
9. Szczeklik A, Gryglewski RJ: Prostaglandins as therapeutic agents in cardiovascular disease. In: Cardiovascular Pharmacology of the Prostaglandins. (Eds. Van Houtte PM, Denolin H, Goossens A), Raven Press, New York, 1982, pp 347-359.
10. 1 bei arterieller Verschlusskrankheit im Stadium III und IV - Ergebnisse einer multizentrischen Studie. Dtsch Med Wochenschr 1987;112:955-959.
11. 1 versus pentoxifylline therapy in chronic arterial occlusive disease - a controlled randomized multicenter study. Vasa Suppl 1989;28:44-49.
12. Balas P, Pagratis N: Experience with buflomedil in peripheral arterial occlusive disease. Angiology 1981;32: 679-685.
13. Clissold SP, Lynch S, Sorkin EM: Pentoxifylline - a buflomedil review of its pharmacokinetic properties and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs 1987;33:430-460.
14. Perego MA, Sergio G, Espureo M, Francisci A, Artale F: Haemodynamic and haemorheological effects of buflomedil in patients with peripheral occlusive arterial disease. Curr Med Res Op 1982;8:178-187.
15. Racenberg J, Intaglietta M, Messmer K: Die Wirkungen des vasoaktiven Medikaments Buflomedil bei der arteriellen Verschlußkrankheit. Fortschr Med 1982;100: 1926-1930.
16. Sunder-Plassmann L, Gandolfo AM, Utz C: Wirksamkeit von Buflomedil bei arterieller Verschlusskrankheit - Beeinflussung des transkutanen Sauerstoffdruckes in einer placebokontrollierten Doppelblindstudie. Muench Med Wochenschr 1984;126:247-248.
17. Truebestein G, Balzer K, Bisler H, Klueken N, Mueller-Wiefel H: Buflomedil in arterial occlusive disease. Results of a controlled multicenter study. Angiology 1984; 35:500-505.
18. 1 treatment of pulmonary hypertension. Am Rev Respir Dis 1987;136: 773-776.
19. 1 in primary pulmonary hypertension. Crit Care Med 1986; 14:72-73.
20. Schroer K: Actions of prostaglandins on the heart. In: Prostacyclin and its Stable Analogue Iloprost. (Eds. Gryglewski RJ, Stock G), Springer, Berlin, 1987, pp 159-178.
21. 1 coronary venous retroperfusion in acute myocardial ischemia: effects on regional left ventricular function and infarct size. J Am Coll Cardiol 1984;3:939-947.
22. 1 in severe left ventricular failure due to chronic coronary heart disease. Am Heart J 1981;102:703-709.
23. 1-treatment in left ventricular heart failure. Prostaglandins Leukotrienes Essent Fatty Acids 1989;38:177-180.
24. 1 in man. Eur J Clin Pharmacol 1987;33:133-137.
25. Erbel R, Schweizer P, Meyer J, Grenner H, Krebs W, Effert S: Bestimmung der Volumina und der Ejektionsfraktion des linken Ventrikels aus dem zweidimensionalen Echokardiogramm bei Patienten mit KHK. Z Kardiol 1980;69:52-61.
26. Weissler AM: Systolic time intervals in heart failure in man. Circulation 1968;37:149.
27. Erbel R, Krebs W, Henn G, Schweizer P, Richter HA, Meyer J, Effert S: Comparison of singleplane and biplane volume determination by two-dimensional echocardiography. I. Asymmetric model hearts. Eur Heart J 1982;3: 469-480.
28. Erbel RP, Schweizer P, Henn G, Meyer J, Effert S: Apikale zweidimensionale Echokardiographie - Normalwerte fuer die monoplane und biplane Bestimmung der Volumina und der Ejaktionsfraktion des linken Ventrikels. Dtsch Med Wochenschr 1982;107:1872-1877.
29. Gordon EP: Reproducibility of left ventricular volumes by two-dimensional echocardiography. J Am Coll Cardiol 1983;2:506-513.
30. Iliceto S, D'Ambrosio G, Marangelli V, Amico A, Di Biase M, Rizzon P: Echo-Dopper evaluation of the effects of heart rate increments on left atrial pump function in normal human subjects. Eur Heart J 1991;12:345-351.
31. Erbel R, Belz GG: Untersuchungen zur Messmethode der systolischen Zeitintervalle. Z Kardiol 1977;66:433-435.
32. Lewis RP, Rittogers SE, Froester WF, Boudoulas H: A critical review of the systolic time intervals. Circulation 1977;56:146-158.
33. Li Q, Belz GG: Systolic time intervals in clinical pharmacology. Eur J Clin Pharmacol 1993;44:415-421.